Neurofibroma plexiforma cervical gigante en una adolescente portadora de neurofibromatosis Tipo I

Yarmuch G, Paula; Chaparro R, Ximena; Fischer S, Cecilia; Benveniste, Samuel; Kaplan Z, Viera.
Rev. chil. dermatol ; 30(4): 406-406, 2014. ilus
Artículo en Español | LILACS | ID: biblio-835988

Documentos relacionados

  1. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
  2. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
  3. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
  4. Selumetinib in the Treatment of Orbital Plexiform Neurofibroma: A Case Report.
  5. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
  6. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
  7. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
  8. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
  9. Miniature Palpebral Plexiform Neurofibroma in Neurofibromatosis Type 2.
  10. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.